References
|
1. |
|
Krantz, MJ, Mehler, PS. Treating opioid dependence: growing implications for primary care. Arch Intern Med 2004; 164:277. |
|
2. |
|
Mattick, RP, Breen, C, Kimber, J, Davoli, M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2002; :CD002209. |
|
3. |
|
Mattick, RP, Kimber, J, Breen, C, Davoli, M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2003; :CD002207. |
|
4. |
|
Kakko, J, Svanborg, KD, Kreek, MJ, Heilig, M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003; 361:662. |
|
5. |
|
Hulse, GK, O'Neil, G, Hatton, M, Paech, MJ. Use of oral and implantable naltrexone in the management of the opioid impaired physician. Anaesth Intensive Care 2003; 31:196. |
|
6. |
|
Foster, J, Brewer, C, Steele, T. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addict Biol 2003; 8:211. |
|
7. |
|
Strang, J, McCambridge, J, Best, D, Beswick, T. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ 2003; 326:959. |
|
8. |
|
Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA 1998; 280:1936. |
|
9. |
|
Federal Register: Methadone: Rules and regulations. The Federal Register 1989; 544:8954. |
|
10. |
|
Hauri-Bionda, R, Bar, W, Friedrich-Koch, A. [Driving fitness/driving capacity of patients treated with methadone]. Schweiz Med Wochenschr 1998; 128:1538. |
|
11. |
|
Ward, J, Hall, W, Mattick, RP. Role of maintenance treatment in opioid dependence [see comments]. Lancet 1999; 353:221. |
|
12. |
|
Sees, KL, Delucchi, KL, Masson, C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 2000; 283:1303. |
|
13. |
|
Dole, VP, Nyswander, M. A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA 1965; 193:646. |
|
14. |
|
Newman, RG, Whitehill, WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet 1979; 2:485. |
|
15. |
|
Nurco, DN, Ball, JC, Shaffer, JW, Hanlon, TE. The criminality of narcotic addicts. J Nerv Ment Dis 1985; 173:94. |
|
16. |
|
Ball, JC, Lange, WR, Myers, CP, Friedman, SR. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav 1988; 29:214. |
|
17. |
|
Novick, DM, Joseph, H, Croxson, TS, et al. Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients. Arch Intern Med 1990; 150:97. |
|
18. |
|
Gowing, LR, Farrell, M, Bornemann, R, et al. Brief report: Methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med 2006; 21:193. |
|
19. |
|
Senay, EC. Opioids: Methadone maintenance. In: Galanter, M, Kleber, HD (Eds), Textbook of Substance Abuse Treatment, 2nd ed, American Psychiatric Press, Inc., Washington, DC 1999. p. 271. |
|
20. |
|
Rettig, RA, Yarmolinski, A (Eds). Committee on Federal Regulation of Methadone Treatment, Division of Biobehavioral Sciences and Mental Disorders, Institute of Medicine: Federal Regulation of Methadone Treatment. National Academy Press, Washington, DC 1995. |
|
21. |
|
Strain, EC, Bigelow, GE, Liebson, IA, Stitzer, ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999; 281:1000. |
|
22. |
|
Johnson, RE, Chutuape, MA, Strain, EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343:1290. |
|
23. |
|
Faggiano, F, Vigna-Taglianti, F, Versino, E, Lemma, P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003; :CD002208. |
|
24. |
|
Caplehorn, JR, Drummer, OH. Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med J Aust 1999; 170:104. |
|
25. |
|
Caplehorn, JR, Drummer, OH. Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. Aust N Z J Public Health 2002; 26:358. |
|
26. |
|
Zador, DA, Sunjic, SD. Methadone-related deaths and mortality rate during induction into methadone maintenance, New South Wales, 1996. Drug Alcohol Rev 2002; 21:131. |
|
27. |
|
Trafton, JA, Minkel, J, Humphreys, K. Determining Effective Methadone Doses for Individual Opioid-Dependent Patients. PLoS Med 2006; 3:e80. |
|
28. |
|
Center for Substance Abuse Treatment (CSAT). Pregnant, substance-abusing women (treatment improvement protocol 2). CSAT, Substance Abuse and Mental Health Services Administration, Rockville, MD 1993. |
|
29. |
|
Weaver, M. Perinatal addiction. In: Graham, AW, and Shultz, TK (Eds), Principles of addiction medicine, 3rd ed, American Society of Addiction Medicine, Inc, Chevy Chase, MD 2003. p.1231. |
|
30. |
|
Wittmann, BK, Segal, S. A comparison of the effects of single- and split-dose methadone administration on the fetus: ultrasound evaluation. Int J Addict 1991; 26:213. |
|
31. |
|
Jarvis, MA, Wu-Pong, S, Kniseley, JS, Schnoll, SH. Alterations in methadone metabolism during late pregnancy. J Addict Dis 1999; 18:51. |
|
32. |
|
McCarthy, JJ, Posey, BL. Methadone levels in human milk. J Hum Lact 2000; 16:115. |
|
33. |
|
Geraghty, B, Graham, EA, Logan, B, Weiss, EL. Methadone levels in breast milk. J Hum Lact 1997; 13:227. |
|
34. |
|
Alford, DP, Compton, P, Samet, JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med 2006; 144:127. |
|
35. |
|
O'Conor, LM, Woody, G, Yeh, HS, et al. Methadone and edema. J Subst Abuse Treat 1991; 8:153. |
|
36. |
|
Kleber, HD. Treatment of narcotic addicts. Psychiatr Med 1985; 3:389. |
|
37. |
|
Ehret, GB, Voide, C, Gex-Fabry, M, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 2006; 166:1280. |
|
38. |
|
Martell, BA, Arnsten, JH, Krantz, MJ, Gourevitch, MN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 2005; 95:915. |
|
39. |
|
Krantz, MJ, Lewkowiez, L, Hays, H, et al. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002; 137:501. |
|
40. |
|
Martell, BA, Arnsten, JH, Ray, B, Gourevitch, MN. The impact of methadone induction on cardiac conduction in opiate users. Ann Intern Med 2003; 139:154. |
|
41. |
|
Pud, D, Cohen, D, Lawental, E, Eisenberg, E. Opioids and abnormal pain perception: New evidence from a study of chronic opioid addicts and healthy subjects. Drug Alcohol Depend 2006; 82:218. |
|
42. |
|
Chu, LF, Clark, DJ, Angst, MS. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 2006; 7:43. |
|
43. |
|
Rosenblum, A, Joseph, H, Fong, C, et al. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA 2003; 289:2370. |
|
44. |
|
Compton, P, Charuvastra, VC, Ling, W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend 2001; 63:139. |
|
45. |
|
Luty, J, O'Gara, C, Sessay, M. Is methadone too dangerous for opiate addiction?. BMJ 2005; 331:1352. |
|
46. |
|
Webster, LR. Methadone-related deaths. J Opioid Manag 2005; 1:211. |
|
47. |
|
Center for Substance Abuse Treatment (CSAT). Methadone-associated mortality: Report of a National Assessment. CSAT Pub. No. 28-03. Substance Abuse and Mental Health Services Administration, Rockville, MD 2004. |
|
48. |
|
Williamson, PA, Foreman, KJ, White, JM, Anderson, G. Methadone-related overdose deaths in South Australia, 1984-1994. How safe is methadone prescribing?. Med J Aust 1997; 166:302. |
|
49. |
|
Zador, D, Sunjic, S. Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. Addiction 2000; 95:77. |
|
50. |
|
Substance Abuse and Mental Health Services Administration (SAMHSA). Mortality data from the Drug Abuse Warning Network, 2000. DAWN Series D-19, DHHS Pub. No. 02-3633. Substance Abuse and Mental Health Services Administration, Rockville, MD 2002. |
|
51. |
|
Bell, J, Zador, D. A risk-benefit analysis of methadone maintenance treatment. Drug Saf 2000; 22:179. |
|
52. |
|
Desmond, DP, Maddux, JF. Deaths among heroin users in and out of methadone treatment. J Maintenance Addict 2000; 1:45. |
|
53. |
|
Buprenorphine: an alternative to methadone. Med Lett Drugs Ther 2003; 45:13. |
|
54. |
|
Fischer, G, Gombas, W, Eder, H, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 1999; 94:1337. |
|
55. |
|
Eder, H, Fischer, G, Gombas, W, et al. Comparison of buprenorphine and methadone maintenance in opiate addicts. Eur Addict Res 1998; 4 Suppl 1:3. |
|
56. |
|
Drummer, OH. Recent trends in narcotic deaths. Ther Drug Monit 2005; 27:738. |
|
57. |
|
Fudala, PJ, Bridge, TP, Herbert, S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003; 349:949. |
|
58. |
|
Mintzer, IL, Eisenberg, M, Terra, M, et al. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 2007; 5:146. |
|
59. |
|
Fiellin, DA, Pantalon, MV, Chawarski, MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 2006; 355:365. |
|
60. |
|
Barry, DT, Moore, BA, Pantalon, MV, et al. Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. J Gen Intern Med 2007; 22:242. |
|
61. |
|
Kakko, J, Gronbladh, L, Svanborg, KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 2007; 164:797. |
|
62. |
|
Tracqui, A, Kintz, P, Ludes, B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 1998; 22:430. |
|
63. |
|
Byrne, A. Reducing deaths among drug misusers. Standard of care in Britain was not addressed. BMJ 2001; 323:513. |
|
64. |
|
Schwetz, BA. From the Food and Drug Administration. JAMA 2001; 285:2705. |
|
65. |
|
Glanz, M, Klawansky, S, McAullife, W, Chalmers, T. Methadone vs. L-alpha-acetylmethadol (LAAM) in the treatment of opiate addiction. A meta-analysis of the randomized, controlled trials. Am J Addict 1997; 6:339. |
|
66. |
|
Clark, N, Lintzeris, N, Gijsbers, A, et al. LAAM maintenance vs methadone maintenance for heroin dependence (Cochrane Review). Cochrane Database Syst Rev 2002; :CD002210. |
|
67. |
|
Rehm, J, Gschwend, P, Steffen, T, et al. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet 2001; 358:1417. |
|
68. |
|
Nordt, C, Stohler, R. Incidence of heroin use in Zurich, Switzerland: a treatment case register analysis. Lancet 2006; 367:1830. |
|
69. |
|
van den, Brink W, Hendriks, VM, Blanken, P, et al. Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ 2003; 327:310. |
|
70. |
|
Steffen, T, Blattler, R, Gutzwiller, F, Zwahlen, M. HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme. Eur J Public Health 2001; 11:425. |
|
71. |
|
Dijkgraaf, MG, van der, Zanden BP, de Borgie, CA, et al. Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials. BMJ 2005; 330:1297. |
|
||||||||||||
|
||||||||||||
|
printer-friendly
format
e-mail
this to a colleague
